FDA clears Teleflex's ArrowEvolution catheter
This article was originally published in Clinica
Executive Summary
The US FDA has granted 510(k) clearance for Teleflex's ArrowEvolution peripherally inserted central catheter. The device incorporates an antimicrobial coating, Chlorag+ard, a chlorhexedine-based solution that has been chemically bonded to the surface of the catheter. This should help protect against central line-associated bloodstream infections and therefore reduce the incidence of hospital-acquired infections, Teleflex believes. The catheter is inserted into a peripheral vein and then advanced through increasingly larger veins, towards the heart, and can be used to deliver chemotherapy or antibiotics. The Limerick, Pennsylvania firm plans to launch the product in the US in the fourth quarter.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.